Back to Awarded Treatment Trials
Awarded Trial: 98-STN-001
Grant ID
98-STN-001
Illness
Schizophrenia
Primary Drug/Intervention
Ethyl Eicosapentanoic Acid
Primary Dosage
3g/day
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Fenton
Sample Size
87
Duration of Study Period for Each Subject
16 weeks
Outcome Measurements
MADRAS, RBANS, AIMS, PANSS
Results
A double-blind, randomly assigned placebo-controlled 16 week trial of omega-3 fatty acid augmentation of antipsychotic treatment in 87 schizophrenic and schizoaffective patients who had residual symptoms was conducted. Improvement in residual symptoms and cognitive impairment for patients treated with 3g/day of ethyl EPA was similar to that seen with placebo.
Publication
Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M. Placebo-controlled trial of omega-3 fatty acid (EPA) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry. 2001 Dec;158(12):2071-4.
Link
http://www.ncbi.nlm.nih.gov/pubmed/11729030
PI Name
Wayne Fenton
Degree
MD
Center
Division of Mental Disorders, Behavioral Research and Aids
Institution
NIH, National Institute of Mental Health
Address
6001 Executive Boulevard, Room 6217, MSC 9621
City or Town
Bethesda
State or Province
MD
Zip or Postal Code
20892
Country
USA
Email Address
wfenton@mail.nih.gov